We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Blood Test Score Detects Hidden Alcohol-Related Liver Disease

By LabMedica International staff writers
Posted on 26 Feb 2026

Fatty liver disease affects nearly one in three adults worldwide and can be driven by metabolic conditions such as obesity and diabetes or by excessive alcohol use. More...

In routine care, it is often difficult to determine whether liver injury is caused by alcohol, especially when drinking is underreported. Missed alcohol-related damage can silently progress for years, leading to hospitalization and preventable deaths. Now, researchers have developed a new blood test score that helps identify when fatty liver disease is likely driven by alcohol, enabling earlier intervention and more personalized care.

The score, called the MetALD-ALD Prediction Index (MAPI), was developed at the University of California San Diego School of Medicine (San Diego, CA, USA) and uses five standard laboratory values already collected during routine primary care and liver clinic visits. By analyzing these commonly available lab results, MAPI estimates whether alcohol-related liver injury may be contributing to fatty liver disease, even when alcohol use is not fully disclosed. The tool is designed to guide clinicians on when additional alcohol-specific testing, such as phosphatidylethanol (PEth), may be necessary.

The researchers evaluated MAPI in more than 500 adults in the San Diego region and approximately 1,800 individuals in Sweden. The results showed that the score outperformed commonly used blood tests in distinguishing alcohol-related liver injury from metabolic causes. The study, published in Gastroenterology, demonstrated that MAPI can help identify patients who may benefit from advanced alcohol testing. While PEth testing is highly accurate, it can be costly or unavailable in many settings, making MAPI a practical screening tool to improve access and efficiency.

MAPI may be particularly valuable in primary care, where most cases of fatty liver disease are first detected. By clarifying the role of alcohol in liver injury, the tool can support earlier lifestyle interventions, guide treatment decisions, and reduce long-term complications. Researchers plan to use MAPI in large observational studies and future clinical trials to further validate its utility. Broader implementation could enhance liver disease classification and improve patient outcomes across diverse health care settings.

“This new score gives clinicians a simple and accessible way to uncover hidden alcohol-related liver injury,” said Rohit Loomba, MD, senior author of the study. “By improving how we classify liver disease, we can help patients achieve better long-term health outcomes.”

Related Links:
UC San Diego School of Medicine


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.